SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Net Margin · Q3 FY2026 · quarter ended Sep 2026

Net margin not reported for Q3 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMSep 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2022
-4130.1%
Year-over-year change
-3857.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How SLS compares with its peers on the latest reported figures

SLS Competitors Peer median
Net Margin for SLS and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202642.0% +334.5 pp+152.0 pp
INCYIncyte CorporationLTM Jun 202627.7% +8.7 pp+15.0 pp
MGNXMacroGenics, Inc.LTM Mar 2026-44.8% -8.2 pp+29.9 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-62.2% +4313.7 pp+63.2 pp
AAPGAscentage Pharma Group InternationalFY2025-216.5% -175.1 pp+204.6 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-297.8% -38.2 pp+120.1 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-465.3% +1360.8 pp—
CBIOCrescent Biopharma, Inc.LTM Mar 2026-1363.9% —+60832.1 pp
IMNMImmunome, Inc.FY2025-3060.0% +180.4 pp—
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
Peer median (excluding SLS) -216.5%+94.6 pp+120.1 pp

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.6M1M000
Cost of Revenue200K100K000
Gross Profit7.4M900K000
Gross Margin97.4%90.0%———
Research & Development21.37M30.27M24.01M19.1M16.02M
Selling, General & Admin11.32M12.58M13.86M12.42M12.25M
Operating Expenses32.69M42.85M37.87M31.51M28.27M
Depreciation & Amortization1.27M457K37.87M31.51M0
EBITDA(18.32M)(31.49M)529K632K(26.86M)
EBITDA Margin-241.1%-3149.3%———
Operating Income(25.29M)(41.95M)(37.87M)(31.51M)(28.27M)
Operating Margin-332.8%-4195.0%———
Interest Income6K317K525K632K1.41M
Interest Expense00000
Other Income / Expenses4.36M649K529K632K1.41M
Income Before Tax(20.94M)(41.3M)(37.34M)(30.88M)(26.86M)
Pre-Tax Margin-275.5%-4130.1%———
Income Tax Expense(237K)0000
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Net Margin-272.4%-4130.1%———
EPS (Basic)(1.34)(2.13)(1.34)(0.50)(0.25)
EPS (Diluted)(1.34)(2.13)(1.34)(0.50)(0.25)
Weighted Avg Shares15.48M19.4M27.78M61.2M109.05M
Weighted Avg Shares (Diluted)15.48M19.4M27.78M61.2M109.05M

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.